Link copied to clipboard!

Fermenta Biotech Lists on India’s NSE

IMT News Desk
IMT News Desk
· 3 min read

Fermenta Biotech Limited, announced the successful listing of its equity shares on the National Stock Exchange of India Limited (NSE).   

  • Equity shares formally listed and admitted to dealings on the NSE 
  • Dual BSE and NSE listing expected to increase accessibility 
  • “Enables participation of wider community ”: Prashant Nagre – Managing Director 

Fermenta Biotech Limited, one of the world’s largest manufacturers of Vitamin D3 API, and a growing portfolio of premium-grade nutritional ingredients, green chemistry, APIs and customized food premixes, today announced the successful listing of its equity shares on the National Stock Exchange of India Limited (NSE).   

Effective 4 August 2026, the Company’s 2,94,30,987 equity shares, of face value ₹5 each, have been listed and admitted to dealings on the NSE under the symbol FERMENTA and ISIN INE225B01021. The Company’s equity shares will continue to remain listed on the BSE under Scrip Code 506414.  

The milestone was commemorated through a ceremonial bell-ringing event held at the NSE’s Exchange Plaza office in Mumbai’s Bandra Kurla Complex. Present were representatives from NSE, Fermenta’s Board and senior leadership team, and other stakeholders.  

The listing marks a milestone in Fermenta’s 75-year journey. Founded in 1951 and listed on the BSE since 1977, the Company has grown from its pharmaceutical and biotechnology foundations into a globally recognised manufacturer serving customers in more than 60 countries, anchored by decades of technical expertise and backed by rigorous global compliance standards and certifications.  

Listed on the BSE since 1977, Fermenta’s NSE listing reflects the Company’s growth, expanding global customer base and widening investor interest. It provides access to shareholders and market participants across both major Indian stock exchanges, supporting broader participation, improved visibility and more efficient price discovery.   

Prashant Nagre, Managing Director, said “Fermenta’s listing on the NSE represents a significant milestone in a landmark year for the Company, as we commemorate 75 years of Fermenta and nearly five decades as a publicly listed enterprise, alongside important recognitions in food safety and workplace culture. It reflects a journey shaped by resilience and a path forward defined by innovation, scale and focus. We will continue to enhance our capabilities across nutrition, food fortification, green chemistry and specialised solutions.  

The NSE listing further strengthens our capital-market presence and reaffirms our commitment to transparency, responsible governance and consistent engagement with shareholders. We extend our sincere appreciation to our promoters, Board, shareholders, employees, customers, partners and all other stakeholders for their continued confidence in Fermenta.”

Read Next

Tata AIA’s ‘Sampoorna Care – Cancer’ To Ease Cancer Treatment
News
August 7, 2026

Tata AIA’s ‘Sampoorna Care – Cancer’ To Ease Cancer Treatment

This insurance bridges the gap by combining cancer protection with regular income support. A cancer diagnosis affects more than a person’s health. It interrupts work, reduces household income and places additional financial pressure on families. Traditional health insurance covers hospital bills, but many families face ongoing expenses such as home loan instalments, rent, school fees […]
Article by: IMT News Desk
Metropolis Healthcare 1QFY27 Reports Strong volume growth
News
August 7, 2026

Metropolis Healthcare 1QFY27 Reports Strong volume growth

METROHL’s 1QFY27 performance was broadly in line with EE across all fronts. According to a release issued, METROHL’s 1QFY27 performance was broadly in line with EE across all fronts. Strong volume growth, higher contribution from margin-accretive TruHealth and traction in the speciality segments continued to support double digit growth. Specialty mix aids margin outperformance: Revenue grew […]
Article by: IMT News Desk
HCG Q1 Revenue Up 13% YoY 
News
August 7, 2026

HCG Q1 Revenue Up 13% YoY 

HCG delivered revenue of INR 6,951 Mn in Q1 FY27, reflecting ~13% YoY growth Healthcare Global Enterprises Limited (HCG), India’s largest dedicated cancer private hospital network, under the brand “HCG”, has announced its financial results for the quarter ended 30th June 2026.  Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd., said, “The strong start to FY27 reflects the resilience of […]
Article by: IMT News Desk
Pfizer Transforms Early Cancer Detection Across Assam
News
August 6, 2026

Pfizer Transforms Early Cancer Detection Across Assam

Partnership with Tata Cancer Care Foundation reaches over 1 million beneficiaries  Pfizer today celebrated its partnership with the Tata Cancer Care Foundation (TCCF), that has reached more than one million beneficiaries across Assam, Jharkhand, Andhra Pradesh, Maharashtra and Odisha by strengthening cancer awareness, early detection and frontline healthcare capacity. The partnership has supported over 993,000 screenings for oral, breast and cervical cancers, trained nearly 25,000 healthcare providers and strengthened community-based referral pathways to support […]
Article by: IMT News Desk